Background and Aims
Introduction
Chronic pain is a major symptom associated with demyelinating autoimmune diseases of the central nervous system (CNS), such as multiple sclerosis and neuromyelitis optica. It has been reported that approximately 50-80% of patients with multiple sclerosis or neuromyelitis optica feel pain (Kanamori et al., 2011; Osterberg et al., 2005; Zhao et al., 2014) , and neuropathic pain is the most prevalent and difficult to treat in these patients (Kessler et al., 2016; Svendsen et al., 2005) .
Neuropathic pain arises from central sensitization (Woolf, 1983) , which is triggered partly by the activation of glial cells (Ikeda et al., 2012; Tsuda et al., 2005) and inflammation (Kawasaki et al., 2008) in the spinal cord. Activating microglia releases brain-derived neurotrophic factor (BDNF), which in turn disinhibits the endogenous inhibitory system or enhances excitatory synaptic transmission in the dorsal horn neurons of the spinal cord (Coull et al., 2005; Ulmann et al., 2008) .
These pathological changes convert innocuous inputs to a nociceptive signal output, leading to pain hypersensitivity. It is also suggested that proinflammatory cytokines such as interleukin-6 (IL-6) can play a critical role in neuropathic pain (Zhou et al., 2016) . IL-6 increased in the spinal cord of peripheral nerve injury model (Arruda et al., 1998; Winkelstein et al., 2001) . Mechanical allodynia was attenuated in the spinal nerve lesion model (Ramer et al., 1998) and chronic constriction injury model (Murphy et al., 1999 ) using IL-6 knockout mice. Intrathecal injection of IL-6 induced allodynia in normal (non-operated) rats (DeLeo et al., 1996) , and peripheral nerve injury-induced mechanical allodynia was attenuated by the spinal injection of anti-IL-6 antibody (Arruda et al., 2000) . Anti-IL-6 receptor antibody also relieved neuropathic pain in spinal cord injury mice (Murakami et al., 2013 ).
IL-6 mainly activates the JAK/STAT transduction pathway, and STAT3 plays an essential role in signaling in the CNS (Imada and Leonard, 2000) . Dominguez et al. demonstrated that intrathecal injection of anti-IL-6 antibody prevented accumulation of phospho-STAT3 in the spinal cord microglia and that inhibiting the STAT3 pathway attenuated mechanical allodynia in the spinal nerve injury model (Dominguez et al., 2008) . In addition to the central mechanism of IL-6 via STAT3 pathway in the spinal cord, reduced the frequency of
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spontaneous inhibitory postsynaptic currents and GABA-induced currents in the spinal cord (Kawasaki et al., 2008) .
Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model of the CNS autoimmune disease, and causes widespread CNS inflammation, demyelination, and locomotor impairments (Baxter, 2007) . Recently, some studies have demonstrated that EAE mice immunized with myelin oligodendrocyte glycoprotein ) peptide show neuropathic pain behavior, glial activation and inflammation such as lymphocyte migration and an increase in proinflammatory cytokines including IL-6 (Dutra et al., 2013; Olechowski et al., 2013; Olechowski et al., 2009) . Although it has been demonstrated that anti-IL-6 receptor monoclonal antibody inhibits the development of clinical symptoms such as paralysis in EAE mice (Serada et al., 2008) , the effects of the anti-IL-6 receptor monoclonal antibody on the neuropathic pain of EAE mice remained unclear. In the present study, therefore, we examined the analgesic effect of anti-IL-6 receptor monoclonal antibody in EAE mice immunized with MOG 35-55 peptide. The relationship between the clinical symptoms and the analgesic effects were also explored in mice with EAE.
Materials and methods

Animals
Female C57BL/6J mice (7 weeks old; Charles River Laboratories Japan, Inc., Kanagawa, Japan) were used. All mice were fed ordinary laboratory chow and allowed free access to water under a constant light and dark cycle of 12 hours. All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals at Chugai Pharmaceutical Co., Ltd, and all experimental protocols were approved by the Animal Care Committee of the institution and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National
Institutes of Health. 
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Experimental design
Experiment 2
To examine the effect of delayed treatment with MR16-1 for a longer period than in Experiment 1, EAE induction method was modified. EAE mice treated with 50 µg MOG 35-55 and 250 ng pertussis toxin were intraperitoneally administered MR16-1 (8 mg/mouse) or vehicle on Day 12. From a week later, pain assessment and tissue collection were performed in onset EAE mice (Clinical score, 2-4). Pain assessments were also conducted before immunization and on Day 12 (Fig. 1B) .
A C C E P T E D M A N U S C R I P T 
Clinical score assessment
Clinical symptoms of EAE were scored according to the following scale: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb paresis; 4, hind limb paralysis; 5, hind limb and fore limb paralysis; 6, moribundity and death.
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Pain assessment
Calibrated von Frey filaments (0.04-2.0 g force) were used to evaluate mechanical allodynia. Mice were placed individually in dark plastic boxes on an elevated wire-mesh bottom plate which allowed full access to the paws. Calibrated von Frey filaments were applied to the plantar surface of the hind paws of mice and the 50% paw withdrawal threshold was determined by using the updown method (Chaplan et al., 1994) .
Immunohistochemistry
Mice were anaesthetized with isoflurane, and transcardial perfusion was carried out with 20 mL of cold phosphate-buffered saline (PBS) followed by 20 mL of cold 4% paraformaldehyde. The L3-L5 segment of the lumbar spinal cord was removed, post-fixed in 4% paraformaldehyde, and placed in a 30% sucrose solution overnight at 4°C. Samples were embedded in optimal cutting temperature (OCT) compound, and frozen slices of spinal cord (10 µm thick) were obtained with a cryostat.
Spinal cord slices were stained by using the following primary antibodies: rabbit polyclonal 
Quantification of cytokines and IL-6 receptor alpha
Mice were anaesthetized with isoflurane, and transcardial perfusion was carried out with 20 mL of cold PBS. The L3-L5 segment of the lumbar spinal cord was removed and frozen in liquid N 2 immediately after isolation and stored in a freezer at −80°C. The spinal cord was weighed and then homogenized with 1 mL Cell Lysis Buffer (Thermo Fisher Scientific, Kanagawa, Japan) per 100 mg of tissue. The homogenates were centrifuged at 16,000 × g for 10 minutes at 4°C. Supernatants were analyzed by using ProcartaPlex immunoassay (Thermo Fisher Scientific) and Mouse IL-6R alpha ELISA (ab203360; Abcam, Cambridge, UK).
Flow cytometry
Mice were anaesthetized with isoflurane, and transcardial perfusion was carried out with 20 mL of 
Cell culture and treatment
Cultured microglial cells (MG6 cells) were purchased from RIKEN Bioresource Center (Nakamichi et al., 2006; Takenouchi et al., 2005) and maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS supplemented with 100 µM β-mercaptoethanol, 10 µg/mL insulin, 100 µg/mL streptomycin, and 100 U/mL penicillin at 37°C under 5% CO 2 . The MG6 cells were seeded on 24-well plates at a density of 1 × 10 5 cells/well. The next day, after washing twice with PBS, the medium was replaced with serum-free medium. After 24-hour incubation, the cells were stimulated for 24 hours with 1-100 ng/mL of mouse IL-6 (406-ML; R&D Systems, Minneapolis, MN, USA) and 100 µg/mL of MR16-1, either as single agents or in combination. After washing twice with PBS, total cellular RNA was extracted and subjected to real-time PCR analysis.
Real-time PCR analysis
Total RNA was isolated from MG6 cells by using an RNeasy Mini kit (Qiagen, Dusseldorf, Germany).
TaqMan real-time PCR was performed with TaqMan Gene Expression Assays for Iba1, P2X4 and BDNF in an ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA).
Gene expression was normalized to the endogenous control, GAPDH.
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Collection of cerebrospinal fluid
Mice were anesthetized with isoflurane. The skin of the neck was shaved, and mice were placed prone on a stereotaxic instrument. The head was secured with the head adaptors and a sagittal incision of the skin was made inferior to the occiput. Working with the aid of a microscope, we separated the subcutaneous tissue and muscles to expose the dura mater of the cisterna magna and the cerebrospinal fluid (CSF) space. The dura mater was blotted dry, and a capillary tube was inserted into the cisterna magna. The CSF passing through the capillary tube was collected and stored in a freezer at −80°C.
ELISA for MR16-1
An immunoplate was coated with 1 μg/mL rabbit polyclonal anti-MR16-1 antibody (prepared in our 
Western blot analysis
Mice were anaesthetized with isoflurane, and transcardial perfusion was carried out with 20 mL of cold PBS. The L3-L5 segment of the lumbar spinal cord was removed and frozen in liquid N 2 immediately after isolation and stored in a freezer at −80°C. Equal amounts of protein extracts were separated on SDS-PAGE and immobilized on PVDF membranes. Immunoblotting was performed with anti-signal transducer and activator of transcription 3 (STAT3) antibodies (Cell Signaling Technology, Danvers, MA, USA) and anti-phospho STAT3 antibodies (Cell Signaling Technology).
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Statistical analyses
All data are expressed as mean and S.E.M. 
Results
Effect of administration of anti-IL-6 receptor antibody at Day 0 or Day 3 on mechanical allodynia and clinical symptoms in EAE mice
The paw withdrawal threshold decreased in vehicle-treated EAE mice at least before Day 7 and persisted until Day 20. Administration of MR16-1 just after immunization (Day 0) or on Day 3 significantly attenuated mechanical allodynia in EAE mice ( Fig. 2A) . MR16-1 also prevented the induction of clinical symptoms in EAE mice (Fig. 2B) .
A C C E P T E D M A N U S C R I P T (Fig. 3) . Representative images of immunohistochemical staining for microglia/macrophages (Iba1), astrocytes (GFAP), and T cells (CD4) in the spinal dorsal horn. Scale bar = 100 μm.
Effect of administration of anti-IL-6 receptor antibody on Day 12 on mechanical allodynia and clinical symptoms in EAE mice
A previous study demonstrated that delaying treatment with MR16-1 until Day 12 failed to suppress clinical symptoms in EAE mice (Serada et al., 2008) . Therefore, we planned to administer MR16-1 on Day 12 after MOG immunization to examine the analgesic effect after EAE onset. On Day 12 after immunization, the paw withdrawal threshold was already significantly decreased in EAE mice, which were divided into 2 groups (EAE + Vehicle and EAE + MR16-1 [Day 12]) using the pain data. After that, MR16-1 was administered intraperitoneally, and we evaluated pain
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
hypersensitivity after EAE onset. As a result, MR16-1 administered on Day 12 significantly improved paw withdrawal threshold in EAE mice at the point of EAE onset (Fig. 4A) . The clinical score was approximately equal between vehicle-treated and MR16-1-treated EAE mice at the point of measuring pain (Fig. 4B) . The length of the period up to disease onset was not also changed by 
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
Effect of administration of anti-IL-6 receptor antibody on Day 12 on glial activation and inflammation in the spinal cord of EAE mice
Immunohistochemical analysis showed that administration of MR16-1 on Day 12 did not decrease the fluorescence intensity of microglia/macrophages, astrocytes, or CD4 + T cells in the spinal dorsal horn of EAE mice at EAE onset (Supplemental Fig. S1 ). Therefore, we examined these cells in more detail by using flow cytometric analysis.
To evaluate microglia exclusive of macrophages, we detected CD45 low CD11b + microglia in the spinal cord of EAE mice (Lelios and Greter, 2014; Wlodarczyk et al., 2015) . CD45 low CD11b + microglia were increased in the spinal cord of Vehicle-treated EAE mice, and were significantly decreased by MR16-1 (Fig. 5A ). On the other hand, MR16-1 did not change the infiltration of Th1, Th2, Th17, or regulatory T cells into the spinal cord of EAE mice ( Fig. 5B-E) . showed the most dramatic increase. MR16-1 did not significantly change these factors (Table 1) .
IL-6 receptor α was also up-regulated in the spinal cord of Vehicle-treated EAE mice, and MR16-1 further increased it (Table 1 ). The averages of IL-23 and IL-10 were dramatically changed in the spinal cord of EAE mice, but the variability of these responses was too great. 
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Detection of MR16-1 in cerebrospinal fluid of EAE mice
To confirm the migration of MR16-1 into the CNS, we measured the concentration of MR16-1 in the CSF of EAE mice. MR16-1 could be detected in the CSF of EAE mice more than 2 weeks after administration, and the peak concentration was >100 µg/mL, which was observed just after administration (Fig. 6A) . The time course of concentration change in CSF was similar to that of serum (Fig. 6A, B) . Furthermore, to compare the CNS transfer rate of MR16-1 in EAE mice with that in normal mice, we collected CSF 2 days after administration of MR16-1 to normal mice. The CSF:serum ratio of MR16-1 concentration 2 days after administration was greater in EAE mice than in normal mice (Table 2) .
Furthermore, we evaluated phosphorylation of STAT3 in the spinal cord of onset EAE mice because IL-6 mainly activates the JAK/STAT3 transduction pathway. As a result, phosphorylation of STAT3 significantly increased in the spinal cord of onset EAE mice, and was significantly decreased by administration of MR16-1 on Day 12 (Fig. 6C) .
Influence of IL-6 on cultured microglia
To assess the direct effect of IL-6 on microglia, we evaluated IL-6-induced gene expression in cultured microglia. IL-6 induced an increase in Iba1 and P2X4 mRNA, which is a key molecule involved in neuropathic pain, in cultured microglia. IL-6 also increased BDNF mRNA, but not significantly, in cultured microglia. MR16-1 significantly prevented the increase in these factors (Fig.   7A , B, C). 
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Discussion
In the present study, the paw withdrawal threshold in EAE mice began to decrease by at least Day 7. This result means that allodynia became apparent prior to neurological deficit, a result that corresponds to previous reports (Dutra et al., 2013; Olechowski et al., 2009) . Administration of MR16-1 just after immunization (Day 0) or on Day 3 prevented mechanical allodynia in EAE mice.
MR16-1 treatment at Day 0 or 3 also attenuated induction of EAE symptoms in this study, which is in agreement with some previous reports that demonstrated that treatment with anti-IL-6 receptor antibody (Serada et al., 2008) or anti-IL-6 antibody (Gijbels et al., 1995) resulted in no development of EAE. These results suggest that early treatment with MR16-1 can exert an analgesic effect via inhibiting EAE onset. Furthermore, administration of MR16-1 on Day 12 post immunization also significantly improved pain hypersensitivity in this study, although it failed to suppress the clinical symptoms of EAE mice. The absence of effect on EAE induction by delayed treatment with MR16-1 corresponds to the results of a previous study (Serada et al., 2008) . Therefore, it is possible that
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IL-6 plays a significant role not only with respect to development of clinical symptoms but also with respect to pain hypersensitivity in EAE mice.
To the best of our knowledge, this is the first report to demonstrate the significant role that IL-6 plays with respect to pain in this EAE model. IL-6-dependent central mechanisms of neuropathic pain are known in several nerve injury models. Intrathecal injection of IL-6 enhanced allodynia in rats with a mononeuropathy (Vissers et al., 2005) . IL-6 was increased in the spinal cords of rats with peripheral nerve injury-induced neuropathic pain (Arruda et al., 1998) and in rats with spinal cord injury-induced neuropathic pain (Guptarak et al., 2013; Murakami et al., 2013) . Spinal injection of anti-IL-6 antibody (Arruda et al., 2000) or anti-IL-6 receptor antibody (Guptarak et al., 2013; Murakami et al., 2013) relieved neuropathic pain. In the present study, IL-6 was dramatically increased in the spinal cords of EAE mice, and intraperitoneal injection of MR16-1 reduced pain hypersensitivity in EAE mice. Notably, MR16-1 could be detected in the CSF of EAE mice, and the CFS:serum ratio of MR16-1 concentration was greater in EAE mice than in normal mice. Because the blood-brain barrier function is disrupted in EAE mice (Liu et al., 2017) , it may be easier for MR16-1 to reach the CNS in EAE mice. Therefore, it is possible that the analgesic effect of MR16-1 was exerted through inhibiting IL-6-dependent central mechanisms in the CNS. With MR16-1 administration on Day 12, especially, the increase in microglial activation, but not astrocyte activation or T cell migration, was reduced in the spinal cords of EAE mice. Furthermore, we demonstrated that phosphorylation of STAT3 significantly increased in the spinal cord of onset EAE mice, and was significantly decreased by administration of MR16-1 on Day 12. Lee et al. also demonstrated that neuropathic pain was caused as a result of IL-6-induced microglial CX3CR1 expression in the spinal cord (Lee et al., 2010) . Dominguez E. et al. demonstrated that the blockade of JAK/STAT3 signaling in spinal microglia attenuated allodynia in peripheral nerve injury rats, and that spinal IL-6 activated microglial JAK/STAT3 signaling (Dominguez et al., 2010) . Therefore, it is suggested that the effect on microglia is one of the analgesic mechanisms of MR16-1.
Accumulating evidence indicates the pivotal role that spinal microglia play in neuropathic pain . Activating microglia disinhibits the endogenous inhibitory system and A C C E P T E D M A N U S C R I P T enhances excitatory synaptic transmission in the dorsal horn neurons of the spinal cord (Coull et al., 2005; Ulmann et al., 2008) , leading to pain hypersensitivity. Microglia express IL-6 receptor, and IL-6 stimulates the proliferation of microglia in vitro (Streit et al., 2000) and the activation of microglia in vivo (Campbell et al., 2014) . Savarin et al. demonstrated that astrocyte-derived IL-6 is a key mediator of the proliferation of microglia in the spinal cord of EAE mice and that intraperitoneal injection of IL-6 neutralizing monoclonal antibody prevented this proliferation (Savarin et al., 2015) . In this study, MR16-1 prevented mechanical allodynia and the increase of microglia in the spinal cord of EAE mice. In addition, Iba1 and P2X4 mRNA was increased in cultured microglia by IL-6 stimulation. These results suggest that MR16-1 prevented microglial activation and proliferation via the inhibition of IL-6 signaling in the spinal cord of EAE mice and that these effects were involved in the analgesic effect of MR16-1. However, the microglia counts/spinal cord still remain significantly elevated in MR16-1-treated EAE mice compared to control mice. Because various cytokines increased in the spinal cord of onset EAE mice as indicated in Table 1 , it is possible that MR16-1 could not prevent the microglial activation and proliferation by the other inflammatory cytokines such as TNFα and IL-1β (Kuno et al., 2005; Monif et al., 2016) . Therefore, delayed treatment of MR16-1 might be partially effective on microglial activation and pain sensitivity in onset EAE mice. On the other hand, our study indicated that delayed treatment with MR16-1 did not decrease the fluorescence intensity of GFAP in the spinal cord of onset EAE mice.
Guptarak J. et al demonstrated that neutralizing mouse IL-6 receptor antibody increased GLT-1 expression, which is abundantly expressed in astrocyte membranes, in spinal cord injury rats (Guptarak et al., 2013) . Therefore, it may be controversial whether anti-IL-6 receptor antibody can affect astrocyte activation in the spinal cord. Further detailed examinations may be needed to clarify the effect of anti-IL-6 receptor antibody on astrocyte activation in EAE mice.
In addition to central mechanisms of neuropathic pain, peripheral sensitization is another major cause of neuropathic pain. In peripheral nerve injury models, upregulation of IL-6 has been observed in damaged dorsal root ganglion neurons (St-Jacques and Ma, 2011) and invading macrophages have been observed in the injured nerve (Ma and Quirion, 2005) . Peripheral IL-6
A C C E P T E D M A N U S C R I P T increases TRPV-1 expression in dorsal root ganglion neurons and causes sensitization of unmyelinated sensory fibers, leading to various types of pathological pain (Brenn et al., 2007; Fang et al., 2015) . It has been recently reported that myelin disruption and injured neurons are observed in the peripheral nervous system of EAE mice, suggesting that peripheral neuropathy is involved in EAE-induced neuropathic pain (Wang et al., 2017) . In contrast, Olechowski et al. indicated that sensory neuropeptides such as calcitonin gene-related peptide and galanin were not changed in EAE mice (Olechowski et al., 2009) . Therefore, there is some uncertainty about whether peripheral mechanisms are involved in EAE-induced neuropathic pain, and the involvement of IL-6 is unclear.
In the present study, IL-6 concentration was not elevated in the serum of EAE mice at onset of the disease compared to control mice (data not shown), so systemic IL-6 is unlikely to influence the sensitivity to pain in EAE mice in the onset phase. However, further detailed examinations will be needed to further clarify the local involvement of IL-6 on the peripheral nervous system such as dorsal root ganglions and peripheral nerves.
There is a limitation in this study. Administration of MR16-1 on Day 12 improved pain hypersensitivity at a time when the clinical score was approximately equal between the vehicle-treated and the MR16-1-treated EAE mice. These results suggest that there is an IL-6-dependent mechanism involved in neuropathic pain of EAE mice independently of clinical symptoms such as paralysis. However, it remains unclear whether or not delayed administration of MR16-1 had essentially no effect on the EAE symptoms and degree of spinal inflammation. Savarin et al. demonstrated that repeated treatment with IL-6 neutralizing antibody from Day 20 after immunization attenuated the clinical score in EAE mice (Savarin et al., 2015) . Therefore, further detailed examinations may be needed to more fully clarify whether neuropathic pain in EAE mice is caused by mechanisms-especially IL-6-dependent mechanisms-that are independent from those involved in the onset of clinical symptoms.
Conclusion
We demonstrated that MR16-1 was effective in alleviating the neuropathic pain of EAE mice. This effect was also observed after the onset of EAE. Our results are expected to clarify the effect of anti-IL-6 receptor antibody on neuropathic pain in patients with demyelinating autoimmune diseases of the CNS.
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Graphical abstract
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A C C E P T E D M A N U S C R I P T Highlights  Anti-IL-6 receptor antibody treatment just after EAE immunization reduced pain.  Delayed treatment with anti-IL-6 receptor antibody also improved pain in EAE mice.  Inhibition of microglial activation might be one of the underlying mechanisms.
